Research from City of Hope in Antineoplastics Provides New Insights (A Phase 1 Study of Venetoclax in Combination with a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed Adults with B-Cell Ph-like ALL).

A recent study conducted by researchers at City of Hope in Duarte, California, explored the use of venetoclax, a BCL-2 inhibitor, in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with B-cell Ph-like acute lymphoblastic leukemia (ALL). The study enrolled 14 patients, with a median age of 33, and found that the addition of venetoclax to the regimen was safe and did not delay counts recovery. All patients achieved complete remission, and a promising rate of minimal residual disease negativity was observed. The study is ongoing, and further analysis will be conducted to determine the correlation between BCL-2 dependency and early minimal residual disease response. [Extracted from the article]